Fourteen post-pubertal subjects (11 male, 3 female) with isolated growth hormone (GH) deficiency were treated with a low dose (0,125 U/kg for the first 4 weeks and thereafter 0·025 U/kg/week) daily sc GH injection for 1 year. Fasting blood samples were collected at entry into the study and subsequently at 3 monthly intervals for estimation of serum cholesterol, high-density lipoproteincholesterol, low-density lipoprotein-cholesterol and lipoprotein(a) [Lp(a)]. Serum Lp(a) increased progressively during the treatment period (by analysis of variance) and was 41% higher at 12 months (P<0·02) despite the fact that five patients showed little or no change. There was no significant change in any of the other lipid fractions. These observations are of concern as Lp(a) is an independent risk factor for cardiovascular disease and should introduce a cautionary note into the enthusiastic efforts to offer GH replacement to all GH deficient adults.
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The potential for treatment of the hypopituitary adult with biosynthetic growth hormone (GH) has highlighted the need to evaluate the anabolic and metabolic requirements for GH in adults. An understanding of the role of GH in regulating lipid metabolism is important in defining the contribution of GH deficiency (GHD) to the increased risk of cardiovascular disease that occurs in hypopituitarism despite apparently adequate replacement therapy with thyroxine, glucocorticoids and sex steroids.' In particular, the effect of GH on serum lipoprotein(a) [Lp(a)] is important, as this lipid fraction is an independent risk factor for cardiovascular disease':", Previous studies addressing this issue have looked at the influence of GH therapy in mixed patient groups, have been of short duration and yielded conflicting results. H 3 In this study, we assessed the effects of 12 months GH replacement on serum lipid concentrations Correspondence: G Wieringa, Department of Biochemistry, Christie Hospital, Manchester M20 4BX, UK. 330 in a group of adults with isolated GH deficiency of childhood onset.
MATERIALS AND METHODS

Subjects
Fourteen Caucasian post-pubertal (11 males and 3 women) subjects with isolated GH deficiency were recruited from the endocrine clinic at the Christie Hospital. Patient characteristics are shown in Table 1 . Further patient details and study design have been described by O'Halloran et al. 14 None had received GH therapy for at least 7 months prior to the start of the study. Recombinant human GH (Genotropin, Kabi Pharmacia, Milton Keynes, UK) was administered as a single daily SC injection. (0,125 U/kg for the first 4 weeks and thereafter 0·025 U/kg/ week). No side effects attributable to treatment were observed. Blood samples were obtained after overnight fast at entry into the study and subsequently at 3 monthly intervals. Fasting samples were analysed at the time of collection and an aliquot frozen at -20°C until assay in a 
Statistics
Serum lipid results were rank ordered at each collection time and then analysed by Friedman's non-parametric two-way analysis of variance (ANDYA). The data were then log transformed and the relative change in an analyte from baseline was calculated for each subject
where 0 = time zero, t = duration of GH treatment, X = individual analyte result and the average change for the group at each time point was then calculated. The significance of a change was determined by paired Student's t-test. Spearman or Pearson correlation coefficient was used to determine association between variables. Results were considered statistically significant at the P < 0·05 level.
RESULTS
Friedman's two-way ANOYA indicated that a significant change had occurred in serum Lp(a) during the treatment period (P<0·03; concentrations (Fig. 1) . Serum Lp(a) concentrations did not correlate with glucose, HbAI or weight. There was also no significant change in HbAl [7·7 (0'5%) versus 6·3 (0'6%), mean (SEM)], glucose (4'8 (0·2)mmol/L versus 4·7
DISCUSSION
In our study cohort with isolated GHD, serum Lp(a) concentrations increased by 41% over baseline values during 12 months of GH replacement. No significant change was detected in serum cholesterol, triglyceride, HDL-cholesterol and LDL-cholesterol concentrations during this period. The significance of the increase in serum Lp(a) concentrations is unknown but potentially worrisome as this lipid fraction is an independent risk factor for cardiovascular disease in the general populaticn.v" The increase in serum Lp(a) concentrations after GH treatment was observed in nine of our patients while five showed little or no change. Whilst measurements of serum insulin-like growth factor (IGF-l) would probably have confirmed compliance in these five patients, this was not thought to be an issue with this cohort of well motivated volunteers. This variable response has also been noted in a study of healthy controls where three of 18 failed to show an increase in Lp(a) after short-term (5-7 days) GH treatment.l? There were no differences in any of the basal features between those who showed an increase in Lp(a) and those who failed to show Il significant change except that four of the five had low baseline Lp(a) values. This possibly indicates an abnormality in the regulation of this fraction. Serum concentration of Lp(a) is under strict genetic control with low values being associated with high molecular weight isoforms of apora)." Variation in the size of apo(a) is in part due to a (0.2) mmol/L at 12 months] or body weight [61'7 (H)kgversus 63·6(3'7) kg]during the study period. hypervariable region at the gene locus." Determination of serum Lp(a) and apo(a) phenotype in these patients and their families may be of value in assessing whether GH mediates alterations in the transcriptional activity of the apo(a) gene locus.
The mechanism(s) responsible for the increase in serum Lp(a) concentration after GH treatment is unknown. Circulating Lp(a) is partially cleared through the LDL receptor'? (reflecting the LDL content of Lpta) whose numbers are known to increase with GH treatment." Thus we would have predicted an enhanced clearance of Lp(a) leading to lower serum Lp(a) concentration, and a decrease in serum cholesterol and LDL-cholesterol. In a short term study (6 months) of a group of patients on multiple hormone replacement therapy an increase in circulating Lp(a) concentrations after GH treatment was noted. In addition, a decrease in serum cholesterol and LDL-cholesterol concentrations were also observed after 6 weeks.f These latter findings were not confirmed in the present study. There was also no correlation between Lp(a) and LDL-cholesterol concentrations and this may be explained by differing metabolism of these lipid fractions through the LDL receptor and/ or other pathways.'? The two to threefold up regulation of hepatic LDL receptors that occurs during GH treatment appears to be insufficient to enhance the clearance of Lp(a) and cause a fall in circulating Lp(a) concentration."
The lack of an effect of prolonged GH treatment on the other lipid fractions in our group is an important observation in view of the atherogenic role of some of these fractions.P GH deficiency may be associated with hypercholesterolaemia? and GH treatment has been reported to be associated with either a decrease 5 , 12, 13 or no change!' in total cholesterol in both normal and GHD subjects. The reasons for these apparently discrepant reports may be due to differences in the timing of the observations. Changes in serum cholesterol after GH treatment may be transient (within the first 6 weeks) with a return to baseline values after more prolonged treatment." Further, the GHinduced changes may be dose dependent. For instance, Salomon! observed a 12% decrease in fasting cholesterol after 6 months of high dose (0'07 U/kg/daily) therapy in GHD adults while others failed to observe any change in normal individuals treated with either high or low-dose GH for a similar time period.'! The situation Growth hormone and lipoprotein (a) 333 with triglycerides is equally variable. Following GH treatment, serum triglyceride concentrations in the GHD individual remain either unchanged-" or increased? while, in normal individuals, triglycerides concentrations show an increase'? or a decrease.P The lack of an effect of GH replacement on lipid fractions other than Lp(a) in our groups may partially reflect their relatively young age, the lower dose and the longer duration of GH replacement and the fact that these patients, apart from GHD, were otherwise hormonally normal.
Whatever the explanation for the rise in Lp(a) in response to GH, the results introduce a cautionary note into the enthusiastic efforts to offer all GHD adults GH replacement. Longterm surveillance studies are required to evaluate the overall cost benefit of growth hormone treatment in the adult.
